JP6448056B2 - ヒトｂｔｎｌ３タンパク質、核酸、および抗体、ならびにそれらの使用 - Google Patents

ヒトｂｔｎｌ３タンパク質、核酸、および抗体、ならびにそれらの使用 Download PDF

Info

Publication number
JP6448056B2
JP6448056B2 JP2015523255A JP2015523255A JP6448056B2 JP 6448056 B2 JP6448056 B2 JP 6448056B2 JP 2015523255 A JP2015523255 A JP 2015523255A JP 2015523255 A JP2015523255 A JP 2015523255A JP 6448056 B2 JP6448056 B2 JP 6448056B2
Authority
JP
Japan
Prior art keywords
btnl3
seq
protein
amino acid
amino acids
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2015523255A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015524413A5 (enExample
JP2015524413A (ja
Inventor
ヘザー エー． アーネット，
ヘザー エー． アーネット，
サビーン エス． エスコバー，
サビーン エス． エスコバー，
ライアン エム． スワンソン，
ライアン エム． スワンソン，
ジョアン エル． バイニー，
ジョアン エル． バイニー，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Inc
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48906512&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP6448056(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of JP2015524413A publication Critical patent/JP2015524413A/ja
Publication of JP2015524413A5 publication Critical patent/JP2015524413A5/ja
Application granted granted Critical
Publication of JP6448056B2 publication Critical patent/JP6448056B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0013—Therapeutic immunisation against small organic molecules, e.g. cocaine, nicotine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
JP2015523255A 2012-07-19 2013-07-18 ヒトｂｔｎｌ３タンパク質、核酸、および抗体、ならびにそれらの使用 Active JP6448056B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261673639P 2012-07-19 2012-07-19
US61/673,639 2012-07-19
PCT/US2013/051097 WO2014015148A1 (en) 2012-07-19 2013-07-18 Human btnl3 proteins, nucleic acids, and antibodies and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017210450A Division JP2018015009A (ja) 2012-07-19 2017-10-31 ヒトｂｔｎｌ３タンパク質、核酸、および抗体、ならびにそれらの使用

Publications (3)

Publication Number Publication Date
JP2015524413A JP2015524413A (ja) 2015-08-24
JP2015524413A5 JP2015524413A5 (enExample) 2016-07-14
JP6448056B2 true JP6448056B2 (ja) 2019-01-09

Family

ID=48906512

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2015523255A Active JP6448056B2 (ja) 2012-07-19 2013-07-18 ヒトｂｔｎｌ３タンパク質、核酸、および抗体、ならびにそれらの使用
JP2017210450A Withdrawn JP2018015009A (ja) 2012-07-19 2017-10-31 ヒトｂｔｎｌ３タンパク質、核酸、および抗体、ならびにそれらの使用
JP2019228946A Withdrawn JP2020039369A (ja) 2012-07-19 2019-12-19 ヒトｂｔｎｌ３タンパク質、核酸、および抗体、ならびにそれらの使用
JP2021214198A Withdrawn JP2022040181A (ja) 2012-07-19 2021-12-28 ヒトｂｔｎｌ３タンパク質、核酸、および抗体、ならびにそれらの使用
JP2023192170A Withdrawn JP2023184751A (ja) 2012-07-19 2023-11-10 ヒトｂｔｎｌ３タンパク質、核酸、および抗体、ならびにそれらの使用

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2017210450A Withdrawn JP2018015009A (ja) 2012-07-19 2017-10-31 ヒトｂｔｎｌ３タンパク質、核酸、および抗体、ならびにそれらの使用
JP2019228946A Withdrawn JP2020039369A (ja) 2012-07-19 2019-12-19 ヒトｂｔｎｌ３タンパク質、核酸、および抗体、ならびにそれらの使用
JP2021214198A Withdrawn JP2022040181A (ja) 2012-07-19 2021-12-28 ヒトｂｔｎｌ３タンパク質、核酸、および抗体、ならびにそれらの使用
JP2023192170A Withdrawn JP2023184751A (ja) 2012-07-19 2023-11-10 ヒトｂｔｎｌ３タンパク質、核酸、および抗体、ならびにそれらの使用

Country Status (7)

Country Link
US (4) US20150166630A1 (enExample)
EP (1) EP2875046B2 (enExample)
JP (5) JP6448056B2 (enExample)
CN (1) CN104703999A (enExample)
AU (3) AU2013292510A1 (enExample)
MX (1) MX366178B (enExample)
WO (1) WO2014015148A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2221063A1 (en) * 2009-02-20 2010-08-25 Ganymed Pharmaceuticals AG Methods and compositions for diagnosis and treatment of cancer
MX2011008430A (es) 2009-02-20 2011-09-29 Ganymed Pharmaceuticals Ag Metodos y composiciones para diagnostico y tratamiento del cancer.
EP3689911B1 (en) 2009-11-11 2024-08-21 Astellas Pharma Inc. Antibodies specific for claudin 6 (cldn6)
EP2404936A1 (en) 2010-07-06 2012-01-11 Ganymed Pharmaceuticals AG Cancer therapy using CLDN6 target-directed antibodies in vivo
EP3026064B1 (en) 2011-05-13 2018-10-17 Ganymed Pharmaceuticals GmbH Antibodies for treatment of cancer expressing claudin 6
US20150166630A1 (en) * 2012-07-19 2015-06-18 Amgen Inc. Btnl3 proteins, nucleic acids, and antibodies and uses thereof
WO2015014376A1 (en) 2013-07-31 2015-02-05 Biontech Ag Diagnosis and therapy of cancer involving cancer stem cells
CN107630085B (zh) * 2017-10-12 2020-09-29 王丽 分子标志物在男性骨质疏松中的应用
CN113227127A (zh) * 2018-06-05 2021-08-06 伦敦大学国王学院 向胃肠系统递送酬载的btnl3/8导引构建体
BR112021013193A2 (pt) 2019-01-07 2021-09-28 Shattuck Labs, Inc. Proteínas heterodiméricas para modulação de células t gama delta

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4474893A (en) 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4965195A (en) 1987-10-26 1990-10-23 Immunex Corp. Interleukin-7
US4968607A (en) 1987-11-25 1990-11-06 Immunex Corporation Interleukin-1 receptors
WO1990005183A1 (en) 1988-10-31 1990-05-17 Immunex Corporation Interleukin-4 receptors
DE3909708A1 (de) 1989-03-23 1990-09-27 Boehringer Mannheim Gmbh Verfahren zur herstellung bispezifischer antikoerper
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO1991018982A1 (en) 1990-06-05 1991-12-12 Immunex Corporation Type ii interleukin-1 receptors
AU8727291A (en) 1990-10-29 1992-06-11 Cetus Oncology Corporation Bispecific antibodies, method of production, and uses thereof
US5262522A (en) 1991-11-22 1993-11-16 Immunex Corporation Receptor for oncostatin M and leukemia inhibitory factor
CA2126967A1 (en) 1992-11-04 1994-05-11 Anna M. Wu Novel antibody construct
US5457035A (en) 1993-07-23 1995-10-10 Immunex Corporation Cytokine which is a ligand for OX40
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
CA2249195A1 (en) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
US6261804B1 (en) 1997-01-21 2001-07-17 The General Hospital Corporation Selection of proteins using RNA-protein fusions
WO1999031241A1 (en) 1997-12-17 1999-06-24 Immunex Corporation Cell surface glycoproteins associated with human b cell lymphomas - ulbp, dna and polypeptides
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
CA2350417C (en) 1998-12-02 2010-02-09 Bristol-Myers Squibb Company Dna-protein fusions and uses thereof
DE69941267D1 (de) 1998-12-10 2009-09-24 Bristol Myers Squibb Co Proteingerüste für antikörper-nachahmer und andere bindende proteine
US6699473B2 (en) 2000-10-13 2004-03-02 Uab Research Foundation Human anti-epidermal growth factor receptor single-chain antibodies
ATE486842T1 (de) 2002-03-12 2010-11-15 Merck Sharp & Dohme Substituierte amide
EP1585760B1 (en) 2002-12-23 2012-08-08 Immunex Corporation Btl-ii nucleic acids, proteins, and antibodies
US7563443B2 (en) 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
EP1702622A1 (en) * 2005-03-18 2006-09-20 CONARIS research institute AG Soluble BTNL2 protein useful to inhibit inflammatory disorders
AR056142A1 (es) 2005-10-21 2007-09-19 Amgen Inc Metodos para generar el anticuerpo igg monovalente
EP2052088A2 (en) 2006-08-02 2009-04-29 Genizon Biosciences Genemap of the human genes associated with psoriasis
EP3663318A1 (en) 2008-01-07 2020-06-10 Amgen Inc. Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
EP2221063A1 (en) * 2009-02-20 2010-08-25 Ganymed Pharmaceuticals AG Methods and compositions for diagnosis and treatment of cancer
WO2011127418A1 (en) 2010-04-09 2011-10-13 Amgen Inc. Btnl9 proteins, nucleic acids, and antibodies and uses thereof
US20150166630A1 (en) * 2012-07-19 2015-06-18 Amgen Inc. Btnl3 proteins, nucleic acids, and antibodies and uses thereof

Also Published As

Publication number Publication date
US20190169259A1 (en) 2019-06-06
JP2023184751A (ja) 2023-12-28
MX366178B (es) 2019-07-01
EP2875046B2 (en) 2025-04-30
US20250361283A1 (en) 2025-11-27
JP2020039369A (ja) 2020-03-19
JP2022040181A (ja) 2022-03-10
WO2014015148A1 (en) 2014-01-23
JP2018015009A (ja) 2018-02-01
US20230192802A1 (en) 2023-06-22
JP2015524413A (ja) 2015-08-24
US20150166630A1 (en) 2015-06-18
AU2013292510A1 (en) 2015-02-05
EP2875046A1 (en) 2015-05-27
AU2018200171A1 (en) 2018-02-01
MX2015000754A (es) 2015-04-16
CN104703999A (zh) 2015-06-10
CA2878400A1 (en) 2014-01-23
AU2019250154B2 (en) 2021-04-22
AU2019250154A1 (en) 2019-10-31
EP2875046B1 (en) 2020-02-26
US11459370B2 (en) 2022-10-04

Similar Documents

Publication Publication Date Title
US20250361283A1 (en) Btnl3 proteins, nucleic acids and antibodies and uses thereof
US10357561B2 (en) BTNL9 proteins, nucleic acids, and antibodies and uses thereof
TWI851650B (zh) Ｇｐｒｃ５ｄ嵌合抗原受體及表現其之細胞
JP2025183273A (ja) ヒトドメインを有する抗ｂ細胞成熟抗原キメラ抗原受容体
CN107835820A (zh) 识别癌症特异性IL13Rα2的CAR T细胞
KR20180057723A (ko) 항-cd30 키메라성 항원 수용체
JP2020536552A (ja) Ｃｔｌａ−４変異型免疫調節タンパク質およびそれらの使用
WO2022179545A1 (zh) 针对cd19和cd22的双靶点star
JP2005523681A (ja) Ｕｌ１６結合タンパク質４
CA2878400C (en) Btnl3 proteins, nucleic acids, and antibodies and uses thereof
MXPA05006535A (es) Acidos nucleicos, proteinas y anticuerpos btl-ii.
EP4382119A1 (en) A kit for use in the treatment of hematological cancer
WO2024121297A1 (en) A kit for use in the treatment of hematological cancer
HK40090152A (en) Anti-b-cell maturation antigen chimeric antigen receptors with human domains

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160527

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160527

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170501

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170731

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170929

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171031

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180329

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20181101

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20181129

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20181129

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20181129

R150 Certificate of patent or registration of utility model

Ref document number: 6448056

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: R3D04

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250